Steatosis Colorimetric Assay Kit

Confirm delete?

Zoom

Cat No: 10012643

Assay Kits - Cell-Based Assays

Steatosis, also known as fatty liver, is a pathological process characterized by abnormal accumulation of lipid within cells. While simple steatosis may not be associated with significant impairment of liver function, excessive fat accumulation can le...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Correlated keywords:

kits fatty liver lipids cells obesity assy kits measuring measurement cell-based assays cell based assay cba adipogenesis NASH non-alcoholic nonalcoholic steatohepatitis NAFLD nonalcoholic fatty liver disease

Product Overview:
Steatosis, also known as fatty liver, is a pathological process characterized by abnormal accumulation of lipid within cells. While simple steatosis may not be associated with significant impairment of liver function, excessive fat accumulation can lead to cirrhosis and even liver failure. The molecular mechanisms involved in non-alcoholic steatosis are poorly understood and little information is available on the pathway(s) responsible for progressive hepatocellular damage following lipid accumulation. Determining hepatotoxicity is an essential component of the drug discovery process and includes steatosis as one of the key parameters evaluated. Cayman’s Steatosis Colorimetric Assay Kit provides a convenient tool for evaluating steatosis risk of drug candidates. In this assay, Oil Red O is used to stain neutral lipids in hepatocytes. Lipid accumulation is then quantified using a plate reader after the dye is extracted from the lipid droplets. Chloroquine is included in the kit as a positive control.

Size	1 ea
Shipping	wet ice
Custom Code	3822.19
UNSPSC code	41116104

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.